Protalix BioTherapeutics (PLX) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.50% |
| Dec 31, 2025 | 17.80% |
| Sep 30, 2025 | -0.70% |
| Jun 30, 2025 | 7.76% |
| Mar 31, 2025 | 6.60% |
| Dec 31, 2024 | 25.25% |
| Sep 30, 2024 | 26.76% |
| Jun 30, 2024 | 6.93% |
| Mar 31, 2024 | 20.83% |
| Dec 31, 2023 | 23.71% |
| Sep 30, 2023 | -20.16% |
| Jun 30, 2023 | 21.29% |
| Mar 31, 2023 | 20.45% |
| Dec 31, 2022 | -16.52% |
| Sep 30, 2022 | 2.89% |
| Jun 30, 2022 | 2.84% |
| Mar 31, 2022 | 7.37% |
| Dec 31, 2021 | 7.09% |
| Sep 30, 2021 | 11.34% |
| Jun 30, 2021 | 20.50% |
| Mar 31, 2021 | -1.19% |
| Dec 31, 2020 | -7.16% |
| Sep 30, 2020 | 18.31% |
| Jun 30, 2020 | -12.47% |
| Mar 31, 2020 | -2.91% |
| Mar 31, 2019 | 2.69% |
| Dec 31, 2018 | -32.55% |
| Sep 30, 2018 | 29.63% |
| Jun 30, 2018 | 0.36% |
| Mar 31, 2018 | 0.36% |
| Dec 31, 2017 | 57.60% |
| Sep 30, 2017 | -5.82% |
| Jun 30, 2017 | -21.50% |
| Mar 31, 2017 | -6.36% |
| Dec 31, 2016 | -2.14% |
| Sep 30, 2016 | 15.88% |
| Jun 30, 2016 | -20.10% |
| Mar 31, 2016 | -18.37% |
| Dec 31, 2015 | 7.83% |
| Sep 30, 2015 | -0.46% |